KIF11 and breast carcinoma: Our population study demonstrated that chemotherapy significantly improved the OS of stage II breast cancer patients with KIF11‐low expression in NKI dataset (logrank P = .004; HR = 0.23; 95% CI, 0.07‐0.63) rather than with the KIF11‐high expression (logrank P = .59; HR = 0.82; 95% CI, 0.38‐1.69) (Figure 4A).